- Residency - University of Texas Health Science Center at San Antonio (1989-1991), Radiation Oncology
- Residency - Ohio State University Hospital (1987-1989), Radiation Oncology
- Medical School - University of Texas Medical Branch at Galveston (1983-1987)
Hak Choy, M.D.
- The Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research
- Radiation Oncology
- Radiation Therapy for Lung Cancer
- Radiation Therapy for Esophageal Cancer
In the course of more than 30 years as a radiation oncologist, Hak Choy, M.D., FASTRO, has worked with almost every new compound that has been developed to combine with radiation, and has distinguished himself as a world-leading expert in chemoradiation therapy.
Dr. Choy is Professor and Chair of the Department of Radiation Oncology at UT Southwestern and holds the Nancy B. and Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research. He graduated from the University of Texas Medical Branch in Galveston and completed a residency in internal medicine/radiation oncology at Ohio State, as well as a residency in radiation oncology at the University of Texas Health Science Center in San Antonio.
Dr. Choy is board certified in therapeutic radiology and was Professor and Vice Chair of the Department of Radiation Oncology at Vanderbilt University before joining UT Southwestern as department chair in 2003. He has been the prime motivator in growing UT Southwestern’s radiation oncology practice to the region’s largest, with two campus locations, including one that opened in 2011.
Dr. Choy is active in the clinic, where he treats patients presenting with small cell lung cancer, non-small cell lung cancer, and metastases of lung cancer to other sites. He continues to be a lead investigator of clinical trials offering new combinations of treatments to patients.
Dr. Choy currently serves as Chair of the Data Safety Monitoring Board and Vice Chair of the Executive Committee of the Radiation Therapy Oncology Group (RTOG). He is also a member of the board of directors of the International Association for the Study of Lung Cancer (IASLC). He is a member of the board of directors of UT Southwestern Health Systems and sits on several other institutional committees. He is a member of the editorial board of Cancer Research and Treatment, Clinical Lung Cancer, and other scientific publications, and he has served as reviewer for the New England Journal of Medicine and many others. Dr. Choy holds a patent for the radio-enhanced delivery of camptothecin-derivative drugs for cancer treatment.
In 2018, he was named a Super Doctor by Texas Monthly.
Meet Dr. Choy
Chair of the Department of Radiation Oncology
The expertise of Hak Choy, M.D., is in developing new drugs that will combine well with radiotherapy to improve outcomes for patients, particularly those with lung cancer.
“At the end of the day, making a true impact on survival for the patient relies on how well we control cancer that we see (with radiation) and how well we control cancer that we don’t see (through chemotherapy), and how well both work in combination.”
Dr. Choy is Chair of the Department of Radiation Oncology and is known globally for his pioneering work, beginning in the early ’90s, showing the benefit of combining paclitaxel and other chemotherapeutic agents with radiation treatment.
More recently, advancements in technology have impacted day-to-day patient care, particularly for those with lung cancer. Dr. Choy has led the Department of Radiation Oncology at UT Southwestern to become, within a few short years, one of the leading institutions in the country housing all of these technologies, and he has instigated training programs to educate physicians on how to effectively use them in the clinic.
Dr. Choy continues to be active in designing national clinical trials that combine chemotherapy with the latest radiation treatment techniques. He holds numerous committee appointments within the Radiation Therapy Oncology Group (RTOG), the national clinical cooperative group for radiation therapy studies funded by the National Cancer Institute (NCI).
- Journal of Clinical Oncology (2004), Member of Editorial Board
- Cancer Research and Treatment (2002), Member of Editorial Board
- Yonsei Medical Journal (2002), Member of Editorial Board
- ALCASE Lung Cancer Manual (2001), Member of Editorial Board
- American College of Radiology
- American Radium Society
- American Society of Clinical Oncology
- Society of Chairs of Academic Radiation Oncology Programs
- Radiation Research Society
- Radiation Research and American Radium Society
- American Society of Therapeutic Radiology and Oncology
- American Association of Cancer Research
- Investigational New Drug (1998), Member of Editorial Board
- Contemporary Oncology (2001), Member of Editorial Board
Principles of Radiation Oncology in CANCER: Principles and Practice of Oncology Review, 6th Edition
DeVita V, Hellman S, Rosenberg S, Kim N, Choy H, et al. (2000), Philadelphia, PA, Lippincott Williams & Wilkins
Chemoradiation in Cancer Therapy
Choy H (2003), Totowa, NJ, Humana Press
- Principles of Radiation Oncology in CANCER: Principles and Practice of Oncology Review, 6th Edition
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H The Lancet. Oncology 2015 Feb 16 2 187-199
International Symposium on Ion Therapy: Planning the First Hospital-Based Heavy Ion Therapy Center in the United States.
Laine A, Pompos A, Story M, Jiang S, Timmerman R, Choy H International journal of particle therapy 2016 2 3 468-471
Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters.
Zhou Z, Folkert M, Cannon N, Iyengar P, Westover K, Zhang Y, Choy H, Timmerman R, Yan J, Xie XJ, Jiang S, Wang J Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2016 May
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Jan
Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
Wardak Z, Choy H Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Dec 34 34 4064-4065
Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies.
Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, Govindan R, Koustensis A, Barker S, Obasaju C Lung cancer (Amsterdam, Netherlands) 2015 Mar 87 3 232-240
SU-E-T-539: Maximum Energy of Helium and Carbon Ions Clinically Needed for Spine, Lung, Prostate and Pancreas Cancer.
Pompos A, Choy H, Jia X, Jiang S, Timmerman R Medical physics 2015 Jun 42 6 3459
Stereotactic ablative body radiation therapy for tumors in the lung in octogenarians: a retrospective single institution study.
Cannon NA, Iyengar P, Choy H, Timmerman R, Meyer J BMC cancer 2014 14 971
A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92.
Becerra CR, Hanna N, McCollum AD, Becharm N, Timmerman RD, DiMaio M, Kesler KA, Yu M, Yan T, Choy H Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013 Nov 8 11 1425-9
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Kim DW, Choy H International journal of radiation oncology, biology, physics 2004 59 2 Suppl 11-20
Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study.
Weinberg R, Kaurin DG, Choy H, Curran WJ, MacRae R, Kim JS, Kim J, Tucker SL, Bonomi PD, Belani C, Starkschall G Journal of applied clinical medical physics / American College of Medical Physics 2004 5 4 15-28
Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells.
Kim JC, Kim JS, Saha D, Cao Q, Shyr Y, Choy H Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2003 Sep 68 3 305-13
Combined modality therapy for non-small cell lung cancer, past, present, and future.
Kim DW, Choy H Lung cancer (Amsterdam, Netherlands) 2003 Dec 42 Suppl 2 S35-40
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
Saha D, Pyo H, Choy H American journal of clinical oncology 2003 Aug 26 4 S70-4
Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, Beauchamp RD The Journal of surgical research 2002 Jun 105 1 43-7
Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant.
MacRae R, Shyr Y, Johnson D, Choy H Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002 Jul 64 1 37-40
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Kim JS, Amorino GP, Pyo H, Cao Q, Choy H Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002 Jan 62 1 61-7
Adjuvant and neoadjuvant treatments for NSCLC.
Vokes EE, Choy H, Gandara D, Mattson K Lung cancer (Amsterdam, Netherlands) 2002 Dec 38 Suppl 4 29-35
Clinical Results of COX-2-Specific Inhibition in Cancer Treatment and Prevention
Orzols R, Choy H New Frontiers: Cox-2 Inhibition in Cancer Care June 2002 Vol 1., No 2
The antiangiogenic agent SU 5416 downregulates phorbol ester-mediated induction of cyclooxygenase-2 expression by inhibiting NADPH Oxidase activity
Saha D, Konjeti SR, Cao C, Morrow JD, Choy H Cancer Research February 2003
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Jan 35 1 56-62
Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012.
Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013 Mar 8 3 373-384
Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer.
MacRae R, Choy H Current oncology reports 2003 Jul 5 4 313-7
Standards of care for anemia management in oncology: focus on lung carcinoma.
Langer CJ, Choy H, Glaspy JA, Colowick A Cancer 2002 Aug 95 3 613-23
Anaphylatoxin C3a enhances mucous glycoprotein release from human airways in vitro.
Marom Z, Shelhamer J, Berger M, Frank M, Kaliner M The Journal of experimental medicine 1985 Apr 161 4 657-68
Chemotherapy and irradiation interaction.
Choy H, Kim DW Seminars in oncology 2003 Aug 30 4 Suppl 9 3-10
Irinotecan in Combination with Radiation Therapy for Small-Cell and Non-Small-Cell Lung Cancer
Wu HG, Choy H Oncology 2002 Vol 16 (No 9 Suppl 9) 13-18
Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study.
Safran H, DiPetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R, Wanebo H, Hughes M, Maia C, Tsai JY, Pasquariello T, Pepperell JR, Cioffi W, Kennedy T, Reeder L, Ng T, Adrian A, Goldstein L, Chak B, Choy H Cancer investigation 2004 22 5 670-7
Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
Choy H, Milas L Journal of the National Cancer Institute 2003 Oct 95 19 1440-52
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
Vokes EE, Choy H Lung cancer (Amsterdam, Netherlands) 2003 Aug 41 Suppl 1 S115-21
Radiotherapy Patters of Care Study in Lung Carcinoma
Movsas B, Moughan J, Komaki R, Choy H Journal of Clinical Oncology March 2003
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Wu HG, Choy H Oncology (Williston Park, N.Y.) 2002 Sep 16 9 Suppl 9 13-8
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
- Bench to Clinic in Concurrent Chemoradiation Therapy
- Spore in Lung Cancer
- Role of SU5416 And Cox-2 Inhibitors as Radiation Sensitizers in Lung Cancer
- Role of COX-2 Inhibitors as a Potential Radiation Sensitizer
- Correlative Studies Using Specimens from Multi-Institutional Prevention and Treatment Trials
- Radiation Therapy for Lung Cancer
- Radiation Therapy for Esophageal Cancer
- Cervical Cancer
- Lung Cancer